Cross-sectional, hypothesis-free proteomic study aimed at identifying novel serum biomarkers in MS. A stepwise, or“triangular” biomarker discovery strategy was employed. This approach began with an ex

NIAID Data Ecosystem90

Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications

靶向质谱蛋白质组学

多发性硬化症生物标志物

Cerebrospinal fluid (CSF) is a promising clinical sample for identification of novel biomarkers for various neurological disorders. Considering its direct contact with brain tissue, CSF represents a v

NIAID Data Ecosystem80

Cortisol awakening response is linked to disease course and progression in multiple sclerosis

神经免疫内分泌

多发性硬化症生物标志物

OBJECTIVES: Dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis has frequently been reported in multiple sclerosis (MS). So far, HPA axis function in MS has predominantly been studied under

NIAID Data Ecosystem100

Median levels and range of biomarkers in serum and CSF samples as determined by ELISA, for the patient groups.

多发性硬化症生物标志物

脑脊液标志物分析

Table 3 shows the median levels of sCD163, CXCL13, NEO, and OPN in serum, CSF, ratio, and index. Index formula: (Biomarker ratio / Albumin ratio). NfL has only been examined in CSF. Abbreviations: RRM

NIAID Data Ecosystem90

Vitamin D status of MS and matched controls based on 25(OH)D levels.

资源简介：

相关数据集